The press releases in this section may contain information
that is no longer current or accurate.

2001
April 10 - Inspire Pharmaceuticals, Inc. Announces Appointment of Joe Schachle as Vice President, Marketing and Sales
February 8 - Inspire Pharmaceuticals, Inc. Reports Fourth Quarter and Year End 2000 Financial Results

2000
November 6 - Inspire Pharmaceuticals Inc. Announces Positive Phase II Clinical Trial of INS365 Ophthalmic for the Treatment of Dry Eye Disease
November 3 - Inspire Pharmaceuticals, Inc. Reports Third Quarter 2000 Financial Results
October 30 - Inspire Pharmaceuticals, Inc. Reports Positive Preclinical Results for Novel Therapeutic Approach for Vaginal Dryness
October 17 - Inspire Pharmaceuticals Announces R&D Appointments
October 3 - Inspire Pharmaceuticals, Inc. c
September 14 - Inspire Pharmaceuticals, Inc. Reports Second Quarter 2000 Financial Results
September 13 - Inspire and Kirin Enter Collaboration for Lung Diagnostics in Asia
August 31 - Inspire Pharmaceuticals Announces Exercise of Over-Allotment Option in Initial Public Offering
August 3 - Inspire Pharmaceuticals Announces Initial Public Offering of Common Stock
May 16 - Inspire Announces Promotions and Appointments of Employees
February 28 - Inspire Pharmaceuticals Files Registration Statement for Initial Public Offering of Common Stock
January 24 - Inspire Pharmaceuticals Names Associate Director of Regulatory, Clinical Affairs
January 5 - Inspire Pharmaceuticals Begins Phase II Clinical Trial of INS365 Ophthalmic Solution for the Treatment of Dry Eye Disease in the U.S.

1999
December 21 - Genentech and Inspire Enter Collaboration for Respiratory Therapeutics
December 13 - Inspire Pharmaceuticals Announces Key Appointments of Chief Business Officer and Senior Director, Preclinical Programs
November 2 - Inspire Completes $12,400,000 Private Placement
October 18 - Inspire Announces Appointments of Key New Employees
July 26 - Inspire Announces Appointment of Don Kellerman, Pharm.D., as Vice President, Development
July 22 - Inspire Pharmaceuticals Announces Launch of Novel Windows-Based 3D Molecular Modeling Software
May 11 - Inspire Pharmaceuticals, Inc. Reports Positive Results for Novel Therapeutic for Dry Eye Disease
May 10 - Inspire Pharmaceuticals Announces Appointments of Senior Directors
May 3 - Inspire Awarded U.S. Key Patent for New Chemical Entities
January 13 - Inspire Pharmaceuticals Announces the Appointment of a Vice President, Corporate Development
January 12 - Inspire Pharmaceuticals Announces the Appointment of Christy L. Shaffer to President and Chief Executive Officer
January 4 - Inspire Pharmaceuticals, Inc. Signs Partnership with Santen Pharmaceutical Co., Ltd. to Develop Novel Therapeutic for Dry Eye Disease

1998
October 17 - Inspire Pharmaceuticals Reports Positive Phase I Results for INS365
September 15 - Inspire Pharmaceuticals Announces the Appointment of Gregory J. Mossinghoff to Senior Director, Operations and Strategic Planning
September 14 - Inspire Pharmaceuticals, Inc. Signs Partnership with Kissei Pharmaceutical Co., Ltd. to Develop Novel Therapeutic for Respiratory Disease
April 29 - Inspire Pharmaceuticals Reports Positive Phase I/II Results for INS316
March 25- Inspire and NeoGenesis to Form Strategic Alliance

1997
October 2- Inspire Raises $13 Million in Private Placement
Copyright © 1999-2004 Inspire Pharmaceuticals Inc. All rights reserved


Ticker
ISPH
Current
3.38
Today's High
3.59
Today's Low
3.30
Pricing Time (EDT)
4:00pm



Public Relations for Inspire Pharmaceuticals, Inc. by:
Euro RSCG Life NRP
200 Madison Avenue
New York, NY 10016
212-845-4266 (phone)
212-845-4260 (fax)
http://www.nrp-euro.com